Tagged with GEN

Generics Over the last ten years, generic medicines have increased access to medicines by over 100% in 7 key therapeutic areas and have provided massive savings for healthcare systems in Europe. In this exclusive interview with Adrian van den Hoven, director general of Medicines for Europe, we discuss the importance of…

Bristol-Meyers Squibb Last week, Bristol-Myers Squibb (BMS) announced that they have entered into a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction with an equity value of approximately $74 billion. Under the terms of the agreement, Celgene shareholders will receive 1.0 Bristol-Myers Squibb share…

Spain Juan Luis Fernández Balaguer, general manager of Laboratorios Combix, the Spanish affiliate of Zydus Cadila, shares the milestones achieved by the company since joining the group and its promising future as one of two European operations. Having formerly served as president of AESEG, he then goes on to offer expert…

Turkey Funda Gücer, country manager at Mylan Turkey, portrays her experience in introducing the company to the Turkish market. She provides her expert insights into current trends in the Turkish generics market and reinforces her company’s commitment to providing quality, affordable treatments.   I think that Turkey is one of the…

USA Chester “Chip” Davis, Jr, the President and CEO of the Association for Accessible Medicines (AAM) weighs in on the issue of drug shortages in America.    An uncertain environment for generic manufacturers imperils the sustainability of patient access to low-cost generic medicines.   The unavailability of prescription medicines can cause physical suffering,…

Spain Luis Serrano, president of the Centre for Genomic Regulation (CRG) in Spain, gives an update on the Centre’s recent history and outlines the need for greater understanding of science and research within the Spanish political class.   When we enter discussions with the different political parties, I feel things are…

Turkey Dr Ferhat Farsi, CEO and founding partner of CinnaGen İlaç, shares the company’s plans to become Turkey’s leading biotech entity and gives insights into the group’s international expansion plans. He highlights the potential of for biotechnology and rare disease therapies in the Turkish market, while also acknowledging the obstacles for…

Spain Joachim Teubner, general manager of Aristo Pharma Iberia, a generics player, highlights the strategy that has helped the company realize rapid growth during a time in which the Spanish generic market has stagnated. Furthermore, he touches on the importance of self-manufacturing for generics companies and the future aspirations of the…

Malaysia Click here to download the Healthcare & Life Sciences Review Malaysia 2018. After recent elections conducted in May 2018 saw Mahathir Mohamad returning as Prime Minister after 15 years to seal a historic victory, Malaysia is again back on its feet. Bolstered by well-established institutions, a fully-functional IP framework and strong…

Opinion Emmanuel Fombu, Global Strategy and Digital Innovation Leader at Johnson & Johnson reflects on health professionals’ fears of AI and their place in the healthcare workforce of the future. Sure, robots might be better at carrying out specific operations or at carrying out monotonous tasks without tiring, but it’s the…

Genomics Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis and Kevin Allison is the director of geo-technology. Together they look at last week’s shock revelation of two CRISPR* babies who were born in China and the added tensions this might cause with the USA.    Aside from the immediate implications for US-China strategic competition, the…

Korea Sunyoung Kim, CEO and founder of ViroMed, reveals his strategy for conquering the US market and the feasibility of his ambitions for ViroMed to become the biotech company with the largest revenues from gene therapy by 2025. He also discusses the areas within the Korean biotech sphere that must develop…